BioStem Technologies, Inc. Asset Acquisition Contingent Consideration Liability Current
BioStem Technologies, Inc. (BSEM) had Asset Acquisition Contingent Consideration Liability Current of $10.00 million as of 2026-06-30, per its S-1 filed 2026-09-18.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:AssetAcquisitionContingentConsiderationLiabilityCurrent · last filed 2026-09-18
- 2026-06-30: Asset Acquisition Contingent Consideration Liability Current $10.00M.
- 2025-12-31: Asset Acquisition Contingent Consideration Liability Current $0.00.
| Period end | Asset Acquisition Contingent Consideration Liability Current |
|---|---|
| 2026-06-30 | $10.00M S-1 · filed 2026-09-18 |
| 2025-12-31 | $0.00 10-Q · filed 2026-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |